Keeping up with oncology drug development is a full-time job. You already have one.
Torralo is your own oncology intelligence desk, inside the AI you already use. Ask a question about a drug, a target or a disease, and get the landscape you would otherwise spend a week assembling.
What CAR-T therapies are in development for multiple myeloma?
Under FDA review
- Anito-cel (anitocabtagene autoleucel), a BCMA CAR-T. Arcellx developed it with Kite, and Gilead bought Arcellx in April 2026.2 Gilead says the FDA plans to decide by 23 December 2026.1Anito-cel, Gilead (from Arcellx and Kite), BCMA CAR-T.2 FDA decision due 23 December 2026.1
Phase 3
- Arlo-cel (arlocabtagene autoleucel), Bristol Myers Squibb, a GPRC5D CAR-T. Positive registrational phase 2 results, September 2026; phase 3 against standard regimens under way.Arlo-cel, Bristol Myers Squibb, GPRC5D CAR-T. Positive phase 2, September 2026; phase 3 under way.3,4
- AZD0120 (GC012F), AstraZeneca, a CAR-T against BCMA and CD19. AstraZeneca is testing it in relapsed myeloma, and against stem cell transplant in newly diagnosed myeloma.AZD0120, AstraZeneca, BCMA and CD19 CAR-T. Relapsed and newly diagnosed myeloma.5,6
Phase 1/2 (1 of 12)
- CT071, CARsgen, a GPRC5D CAR-T, in relapsed myeloma.7
Already approved: Abecma and Carvykti in the US, and Fucaso and zevor-cel in China.Approved: Abecma and Carvykti (US), Fucaso and zevor-cel (China).8,9,10,11
11 sources · As of 11 November 2026
- Gilead and Kite, ASH 2026 data release, 4 November 2026
- Gilead, completion of the Arcellx acquisition, 27 April 2026 (at that time Gilead gave 2 February 2027 as the FDA date)
- Bristol Myers Squibb, QUINTESSENTIAL phase 2 topline results, 8 September 2026
- ClinicalTrials.gov NCT06615479, arlo-cel phase 3 (QUINTESSENTIAL-2)
- ClinicalTrials.gov NCT07391657, AZD0120 phase 3 in relapsed myeloma (DURGA-4)
- ClinicalTrials.gov NCT07735637, AZD0120 phase 3 versus transplant (DURGA-6)
- ClinicalTrials.gov NCT06333509, CT071 phase 1/2
- FDA approval letter, Abecma, 26 March 2021
- FDA approval letter, Carvykti, 28 February 2022
- IASO Bio and Innovent, China approval of Fucaso, 3 July 2023
- CARsgen, China approval of zevor-cel, 1 March 2024
What is approved or in phase 3 for triple-negative breast cancer?
Approved in the US for TNBC
- Datroway (datopotamab deruxtecan), AstraZeneca and Daiichi Sankyo, a TROP2 ADC. First line since 22 May 2026, for patients who can’t take a PD-1 or PD-L1 drug.Datroway, AstraZeneca and Daiichi Sankyo, TROP2 ADC. First line, May 2026.1
- Trodelvy, Gilead, a TROP2 ADC. Later lines since April 2020. First line since June 2026: alone if a PD-1 or PD-L1 drug is not an option, or with Keytruda at PD-L1 CPS 10 or more.Trodelvy, Gilead, TROP2 ADC. Since 2020; first line since June 2026.2,3
- Keytruda, Merck, with chemotherapy. PD-L1-positive metastatic disease since November 2020; high-risk early disease, around surgery, since July 2021.Keytruda, Merck, with chemo. Metastatic since 2020, early since 2021.4,5
Phase 3 (3 of 23 open trials)
- Sac-TMT, Kelun-Biotech and Merck, TROP2 ADC. First line, against chemotherapy.Sac-TMT, Kelun-Biotech and Merck, TROP2 ADC. First line.6
- Datroway with Imfinzi, AstraZeneca. First line, PD-L1-positive disease.Datroway with Imfinzi, AstraZeneca. First line, PD-L1-positive.7
- Pumitamig (BNT327), BioNTech, PD-L1 and VEGF-A bispecific. First line.Pumitamig, BioNTech, PD-L1 and VEGF-A bispecific. First line.8
Chinese-developed and approved in China: sac-TMT (pretreated metastatic disease, November 2024) and toripalimab (Junshi, PD-1, first line with chemotherapy, 2024).Chinese-developed, approved in China: sac-TMT and toripalimab (Junshi), both 2024.9,10
10 sources · As of 11 November 2026
- FDA, approval of datopotamab deruxtecan in TNBC, 22 May 2026
- FDA, Trodelvy label, April 2021 (first approved 22 April 2020)
- FDA, first-line approval of sacituzumab govitecan, 24 June 2026
- Merck, Keytruda approval in metastatic TNBC, 13 November 2020
- FDA, pembrolizumab in high-risk early-stage TNBC, 26 July 2021
- ClinicalTrials.gov NCT06841354, sac-TMT phase 3 (TroFuse-011)
- ClinicalTrials.gov NCT06103864, Dato-DXd phase 3 (TROPION-Breast05)
- ClinicalTrials.gov NCT07173751, pumitamig phase 3 (ROSETTA Breast-01)
- Kelun-Biotech, sac-TMT’s China approvals
- Junshi, toripalimab’s TNBC indication on China’s reimbursement list, November 2024
Which Chinese antibody-drug conjugates have reached phase 3?
Approved in China (6, from company announcements)
- Disitamab vedotin (Aidixi), RemeGen, HER2. Gastric cancer, June 2021.Disitamab vedotin, RemeGen, 2021.1
- Sac-TMT, Kelun-Biotech and Merck, TROP2. Breast cancer, November 2024.Sac-TMT, Kelun-Biotech, 2024.2
- Trastuzumab rezetecan, Hengrui, HER2. HER2-mutant lung cancer, May 2025.Trastuzumab rezetecan, Hengrui, 2025.3
- Trastuzumab botidotin, Kelun-Biotech, HER2. Breast cancer, October 2025.Trastuzumab botidotin, Kelun, 2025.4
- Becotatug vedotin, Lepu Biopharma, EGFR. Nasopharyngeal cancer, October 2025.Becotatug vedotin, Lepu, 2025.5
- Iza-bren (izalontamab brengitecan), SystImmune and Bristol Myers Squibb, EGFR and HER3. Nasopharyngeal cancer, June 2026; esophageal cancer, July 2026.Iza-bren, SystImmune and BMS, 2026.6,7
Filed in China
- IBI343, Innovent, CLDN18.2. Gastric cancer, accepted June 2026.IBI343, Innovent, CLDN18.2. June 2026.8
- YL201, MediLink and Roche, B7-H3. Nasopharyngeal cancer, July 2026.YL201, MediLink and Roche, B7-H3. July 2026.9
Phase 3 (3 of 21)
- Sone-Ve (sonesitatug vedotin), KeyMed, licensed to AstraZeneca, CLDN18.2. Improved survival in pretreated gastric cancer (July 2026).Sone-Ve, KeyMed and AstraZeneca, CLDN18.2. Improved survival, July 2026.10,11
- Risvutatug rezetecan, Hansoh and GSK, B7-H3. Small-cell lung cancer.Risvutatug rezetecan, Hansoh, GSK.12,13
- Zocilurtatug pelitecan, Zai Lab, DLL3. Small-cell lung cancer.Zocilurtatug pelitecan, Zai Lab, DLL3.14
14 sources · As of 11 November 2026
- RemeGen, China approval of disitamab vedotin, 9 June 2021
- Kelun-Biotech, sac-TMT’s China approvals
- Hengrui, announcement of the China approval of trastuzumab rezetecan, 29 May 2025
- Kelun-Biotech, announcement of the China approval of trastuzumab botidotin, 17 October 2025
- Lepu Biopharma, China approval of becotatug vedotin, October 2025
- SystImmune, first China approval of iza-bren, June 2026
- SystImmune, second China approval of iza-bren, July 2026
- Innovent, IBI343 phase 3 result and China filing, June 2026
- MediLink, YL201 China filings, 2 September 2026 (nasopharyngeal filing accepted 17 July 2026)
- AstraZeneca, licence for CMG901 (Sone-Ve), 23 February 2023
- AstraZeneca, CLARITY-Gastric01 result, 27 July 2026
- GSK, licence for HS-20093 from Hansoh, December 2023
- ClinicalTrials.gov NCT07099898, risvutatug rezetecan phase 3 (EMBOLD SCLC-301)
- ClinicalTrials.gov NCT07218146, zocilurtatug pelitecan phase 3 (DLLEVATE)
How does it work?
Connect.
You add Torralo (an MCP server) to the AI assistant you already use (ChatGPT, Claude, Copilot, and more). It takes a minute.
Ask.
You ask your question in plain English. Your assistant uses Torralo on its own. If it needs a nudge, tell it: “Use Torralo.”
Build.
You ask your assistant to turn the answer into slides, infographics or spreadsheets, and to update them whenever you need.
What data does Torralo have?
Every answer cites its source: company pipelines and filings, regulators, press releases and trial registries.
Competitive landscapes
8,143 cancer drugs and 41,957 trials, by target, biomarker or disease, with owner and stage
Catalyst calendar
3,370 upcoming readouts, filings and regulatory decisions
Company pipelines
3,204 companies with 100% pipeline coverage of the top 200 companies
Approval histories
2,689 approvals by indication, date and patient population, covering every cancer drug approved in the US and EU
Deal terms
654 licensing deals, acquisitions and partnerships, with the upfronts and milestones companies disclosed
Pivotal trial results
32,052 efficacy results from 4,789 trials: response rates, survival and safety, side by side
How does information get into Torralo?
A team of AI agents does the work, from the first fetch to the filed record.
Collect.
Agents gather data from companies, regulators, and registries around the globe.
Sort.
Documents are separated and sorted by type.
Analyze.
Important facts are extracted and summarized.
Check.
Facts are compared again to original sources and corrected if errors have emerged.
File.
The most important data is organized for quick retrieval.
Answer.
Your AI assistant asks a question. Torralo looks it up in those records and sends back the answer with its sources.
Who is behind all this?
Hi, I’m Mike Italia. I help healthcare and life sciences companies build AI products. My client work requires me to stay current on oncology. I got tired of piecing the picture together from registries, press releases and filings, so I built Torralo.
Products that do this already exist. I couldn’t justify the price, and neither can most startups, small companies and independent consultants. The price is high because vendors pay rooms full of analysts to keep the data current. AI changes that math. I run Torralo myself, with a team of AI agents, and I’m pricing it for the people large vendors leave out.
Get an invitation to the beta
Leave your email. I’ll contact you when the beta is ready and invite you to take part.